Back to Search Start Over

The human IL-15 superagonist ALT-803 directs SIV-specific CD8 + T cells into B-cell follicles.

Authors :
Webb GM
Li S
Mwakalundwa G
Folkvord JM
Greene JM
Reed JS
Stanton JJ
Legasse AW
Hobbs T
Martin LD
Park BS
Whitney JB
Jeng EK
Wong HC
Nixon DF
Jones RB
Connick E
Skinner PJ
Sacha JB
Source :
Blood advances [Blood Adv] 2018 Jan 23; Vol. 2 (2), pp. 76-84.
Publication Year :
2018

Abstract

Sequestering of latent HIV in follicular helper T cells within B-cell follicles that largely exclude cytotoxic T cells is a major barrier to cellular immune-based approaches to eradicate HIV. Here, we show that the clinical-grade human interleukin-15 (IL-15) superagonist ALT-803 activates and redirects simian immunodeficiency virus (SIV)-specific CD8 <superscript>+</superscript> T cells from the peripheral blood into B-cell follicles. In agreement with the increased trafficking of SIV-specific cytotoxic T cells to sites of cryptic viral replication, lymph nodes of elite controlling macaques contained fewer cells expressing SIV RNA or harboring SIV DNA post-ALT-803 treatment. These data establish ALT-803 as an immunotherapeutic for HIV and other chronic viral pathogens that evade host immunity by persisting in B-cell follicles.<br /> (© 2018 by The American Society of Hematology.)

Details

Language :
English
ISSN :
2473-9537
Volume :
2
Issue :
2
Database :
MEDLINE
Journal :
Blood advances
Publication Type :
Academic Journal
Accession number :
29365313
Full Text :
https://doi.org/10.1182/bloodadvances.2017012971